“Venturing Forward, Innovating for Impact” | Managing Partner | Venture Capital, Strategic M&A Advisory, Investment Banking | Board of Directors | Healthcare, Life Sciences, and Frontier
According to the latest Pitchbook data, venture creation in biotech hit its slowest quarterly pace in eight years during 1Q 2024. With just over 60 new biotechs raising their first round of financing, the sector’s company formation activity has slowed 50-60% from its historic peak in 2021. Thank you Bruce Booth for penning your views on why this is a good thing. -Contraction in venture creation IS a healthy dynamic for the sector. -We need to ensure that the best ideas are getting advanced by the sector. -Greater discipline should translate into better returns in the long term for LPs and GPs/ VC #Venturecapital #Startups
Great insight, Bruce. Have you considered leveraging predictive analytics to identify emerging trends, diversifying investment strategies to embrace not just biotech but the intersection of tech and healthcare for robust portfolio growth?